ATE406881T1 - Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung - Google Patents

Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Info

Publication number
ATE406881T1
ATE406881T1 AT02733811T AT02733811T ATE406881T1 AT E406881 T1 ATE406881 T1 AT E406881T1 AT 02733811 T AT02733811 T AT 02733811T AT 02733811 T AT02733811 T AT 02733811T AT E406881 T1 ATE406881 T1 AT E406881T1
Authority
AT
Austria
Prior art keywords
alpha
beta unsaturated
radiation
toxicity
arylsulphones
Prior art date
Application number
AT02733811T
Other languages
German (de)
English (en)
Inventor
Premkumar Reddy
Ramana Reddy
Stephen Cosenza
Lawrence Helson
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc filed Critical Univ Temple
Application granted granted Critical
Publication of ATE406881T1 publication Critical patent/ATE406881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02733811T 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung ATE406881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28

Publications (1)

Publication Number Publication Date
ATE406881T1 true ATE406881T1 (de) 2008-09-15

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733811T ATE406881T1 (de) 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Country Status (10)

Country Link
US (1) US6667346B2 (OSRAM)
EP (1) EP1370253B8 (OSRAM)
JP (1) JP4302986B2 (OSRAM)
KR (1) KR100850331B1 (OSRAM)
AT (1) ATE406881T1 (OSRAM)
AU (1) AU2002305942B2 (OSRAM)
CA (1) CA2439288C (OSRAM)
DE (1) DE60228692D1 (OSRAM)
IL (2) IL157541A0 (OSRAM)
WO (1) WO2002069892A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028828A1 (en) 2000-10-05 2002-04-11 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
MXPA04008356A (es) * 2002-02-28 2005-09-12 Univ Temple (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos.
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
US7744889B2 (en) * 2003-11-14 2010-06-29 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
US7649013B2 (en) * 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
EP1740530B8 (en) * 2004-03-16 2017-03-01 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
EP1773310B9 (en) 2004-06-24 2012-04-25 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
ATE497768T1 (de) * 2004-07-19 2011-02-15 Onconova Therapeutics Inc Formulierungen für die parenterale verabreichung von (e)-2,6-dialkoxystryryl 4-substituierten benzylsulfonen
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
EP1841420B1 (en) * 2005-01-05 2011-12-07 Temple University - Of The Commonwealth System of Higher Education Treatment of drug-resistant proliferative disorders
AU2006216544B2 (en) * 2005-02-25 2012-04-05 Onconova Therapeutics, Inc. Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
US8106033B2 (en) * 2005-03-11 2012-01-31 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007016201A2 (en) 2005-07-29 2007-02-08 Onconova Therapeutics, Inc. FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
EP2046343B1 (en) * 2006-07-28 2014-05-14 Onconova Therapeutics, Inc. Formulations of radioprotective alpha, beta unsaturated aryl sulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008076270A2 (en) * 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
JP2012504645A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
WO2010075026A2 (en) * 2008-12-16 2010-07-01 Onconova Therapeutics Inc Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
WO2010132725A2 (en) 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
JP5882296B2 (ja) * 2010-03-24 2016-03-09 オンコノバ・セラピューティックス・インコーポレーテッド 創傷の予防及び治療のための組成物及び方法
EA023535B9 (ru) * 2010-03-26 2016-11-30 Онконова Терапьютикс, Инк. Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
CN110776447A (zh) 2012-09-20 2020-02-11 坦普尔大学 取代的烷基二芳基衍生物、制备方法和用途
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
AU2015204239B2 (en) * 2014-01-06 2018-04-19 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
JP7324930B2 (ja) * 2019-07-18 2023-08-10 フアシアシェンシェン ファーマシューティカル ベイジン カンパニー リミテッド カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299718B6 (cs) 1997-10-03 2008-10-29 Temple University - Of The Commonwealth System Ofhigher Education Styrylsulfonová sloucenina a farmaceutický prostredek ji obsahující
US6201154B1 (en) 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
JP4596651B2 (ja) 1999-04-02 2010-12-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｅ）−スチリルスルホン抗癌剤
AU3381399A (en) * 1999-04-02 2000-10-23 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
WO2001076592A1 (en) * 2000-04-06 2001-10-18 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
CA2439255C (en) * 2001-02-28 2011-01-04 Temple University Of The Commonwealth System Of Higher Education N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Also Published As

Publication number Publication date
US6667346B2 (en) 2003-12-23
EP1370253B1 (en) 2008-09-03
KR100850331B1 (ko) 2008-08-04
JP2004525908A (ja) 2004-08-26
CA2439288C (en) 2011-08-09
JP4302986B2 (ja) 2009-07-29
EP1370253A2 (en) 2003-12-17
IL157541A0 (en) 2004-03-28
IL157541A (en) 2010-05-31
CA2439288A1 (en) 2002-09-12
EP1370253A4 (en) 2005-08-17
AU2002305942B2 (en) 2006-10-26
US20030060505A1 (en) 2003-03-27
WO2002069892A3 (en) 2002-11-07
DE60228692D1 (de) 2008-10-16
KR20030086596A (ko) 2003-11-10
WO2002069892A2 (en) 2002-09-12
EP1370253B8 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
ATE406881T1 (de) Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
Schuster et al. Side effects in cold plasma treatment of advanced oral cancer—Clinical data and biological interpretation
EA200000087A1 (ru) Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
MXPA03003354A (es) Dispositivos medicos revestidos para el tratamiento de una enfermedad vascular.
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
Montoro et al. Infrared LED irradiation photobiomodulation of oxidative stress in human dental pulp cells
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
Anné et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
Grdina et al. Relationships between cytoprotection and mutation prevention by WR-1065
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
DE60044092D1 (de) Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
Blakley et al. Differences in Ototoxicity across Species.
ATE442188T1 (de) Bestrahlungseinrichtung
ATE375163T1 (de) Zusammensetzungen enthaltend vernix und ein uv- schutzmittel, und deren verwendung
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING THE SIDE EFFECTS OF RADIATION THERAPY AND CHEMOTHERAPY
AR026004A1 (es) Pirroles substituidos.
ATE551058T1 (de) Zusammensetzungen enthaltend tempamine und deren verwendung zum schutz vor oxidativer schädigung
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties